Abstract
The clinical efficacy of chemotherapy relies in part on its ability to potentiate anti-tumor immune responses. Recent work shows that several chemotherapeutic drugs induce intra-tumoral expression of lymphocyte-attracting chemokines, leading to clinical responses. Here, we argue that such knowledge should be used to screen for novel anti-tumor treatments.